Joe Putnam
Faculty Member
Last active: 3/27/2014

Predicted pulmonary function and survival after pneumonectomy for primary lung carcinoma.

Putnam JB, Lammermeier DE, Colon R, McMurtrey MJ, Ali MK, Roth JA
Ann Thorac Surg. 1990 49 (6): 909-14; discussion 915

PMID: 2369189 · DOI:10.1016/0003-4975(90)90864-3

Between 1982 and 1987, 139 patients with primary carcinoma of the lung were treated with pneumonectomy. Thirty-nine patients (28%) were in clinical stage I, 10 (7%) were in clinical stage II, and 90 (65%) were in clinical stage III. Overall actuarial 3-year survival was 33%. Actuarial 3-year survival for patients in clinical stage I was 44%; for those in clinical stage II, 48%; and for those in clinical stage III, 28%. Risk factors for operative mortality examined included preoperative forced vital capacity (FVC) of 2.13 L or less and forced expiratory volume in 1 second (FEV1) of 1.65 L or less, percent predicted FVC of 64% or less and FEV1 of 65% or less, predicted postoperative FVC of 1.31 L or less and FEV1 of 0.89 L or less, and predicted postoperative percent predicted FVC of 41% or less and FEV1 of 34% or less. Operative deaths occurred only in clinical stage III patients (7/90 or 8%). Patients with compromised pulmonary function based on one or more of the examined risk factors were at increased risk for death (2/10) compared with patients with better pulmonary function (5/80 or 6.25%). Actuarial 3-year survival for high-risk clinical stage III patients ranged from 0% to 16% compared with 28% for other clinical stage III patients. Thirty-day mortality for pathological stage III patients was 6.3% (5/79), and 3-year actuarial survival was 24%. No patient in pathological stage III who was at high risk survived beyond 3.1 years. Select individuals with adequate pulmonary function and stage III disease can achieve substantial long-term survival after pneumonectomy.(ABSTRACT TRUNCATED AT 250 WORDS)

MeSH Terms (21)

Actuarial Analysis Adenocarcinoma Adult Aged Aged, 80 and over Carcinoma Carcinoma, Squamous Cell Female Follow-Up Studies Forced Expiratory Volume Humans Lung Lung Neoplasms Male Middle Aged Neoplasm Staging Pneumonectomy Probability Risk Factors Survival Rate Vital Capacity

Connections (1)

This publication is referenced by other Labnodes entities: